Emyria Limited (EMD.AX)
Emyria Limited operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Leederville, WA, AU. The stock last traded at $0.04, up 0.00% on the session, giving a market capitalisation of $25.8M. Its beta of 0.03 implies it has historically moved less than the broad market.
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Emyria Limited is most often compared with the following Healthcare names: